We are excited to announce a major scientific milestone from the Brainify.AI team: our latest research article, “EEG-Based Prediction of Placebo Response Using Deep Convolutional Neural Networks,” has just been published in the prestigious journal Neuroinformatics.
This publication, led by our CEO and co-founder Mariam Khayretdinova, highlights Brainify.AI’s ongoing commitment to advancing neuroscience and precision psychiatry through AI-powered brainwave analysis.
The Challenge: Placebo Response in CNS Trials
The placebo effect remains one of the most persistent challenges in neuroscience and psychiatric drug development, often obscuring true treatment efficacy and leading to costly late-stage trial failures. Despite decades of research, reliable, objective biomarkers to predict placebo response remain elusive—until now.
Our Approach: Leveraging EEG and Deep Learning
In this pioneering study, Mariam and our research team developed a deep convolutional neural network (CNN)designed to analyze high-density electroencephalography (EEG) data collected from clinical trial participants. By applying advanced machine learning to the world’s largest proprietary EEG dataset, our model learns subtle brainwave patterns that differentiate placebo responders from non-responders before treatment even begins.
Key Highlights:
-
Data-Driven Modeling: Utilized over 10,000 high-quality EEG recordings across diverse CNS trial cohorts.
-
Technical Innovation: Our CNN architecture captures both spatial and temporal EEG features, offering robust predictive accuracy in real-world, multicenter datasets.
-
Clinical Impact: The model significantly outperforms traditional statistical and non-neural approaches, enabling early identification of likely placebo responders.
Why This Matters
Predicting placebo response is a game-changer for CNS clinical trials and drug development:
-
Smarter Trials: Sponsors can stratify patients, optimize study arms, and reduce trial noise, increasing the likelihood of detecting true drug efficacy.
-
Accelerated Innovation: Pharma companies can “rescue” promising drug candidates that might otherwise be lost to placebo effects.
-
Personalized Psychiatry: Clinicians can tailor interventions and avoid unnecessary exposure to ineffective treatments.
A Word from Our CEO
“Publishing in Neuroinformatics validates our belief that EEG and AI, when combined at scale, can reveal novel biomarkers that drive smarter, faster drug development and truly personalized care. We’re grateful to our partners, our talented team, and the broader neuroscience community for supporting this journey.” Mariam Khayretdinova, CEO & Co-Founder, Brainify.AI
Learn More
We invite you to read the full article here and join us as we continue to unlock the power of brainwaves and AI for the future of mental health.
Stay tuned for more updates from the Brainify.AI team as we continue to translate deep tech into real-world clinical impact.
